Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MMP12 | P39900 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309481 | 1.00 | CA1 (0.47) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL2169970 | 1.00 | CA1 (0.47) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL8653916 | 0.90 | ALDH1A1 (0.48) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL1115743 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL308568 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL309095 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL308565 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL31206852 | 0.84 | CA12 (0.45) | CA1CA2CA9PYGBGAA | |
| SCHEMBL22346509 | 0.83 | CA12 (0.48) | CA1CA2CA9PYGBGAA | |
| SCHEMBL23066316 | 0.81 | PYGB (0.41) | CA1CA2CA9PYGBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260009800-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | UNIV ARIZONA (US) | 2026-01-08 | — | — | US | claimed |
| US-20250164507-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CARDIOMYOPATHY IN A FELINE | Société des Produits Nestlé S.A. (CH) | 2025-05-22 | — | — | US | claimed |
| US-20230015727-A1 | Methods, Kits and Compositions for Diagnosing and Treating Renal Disease | HILL'S PET NUTRITION, INC. (US) | 2023-01-19 | — | — | US | claimed |
| EP-2991683-A1 | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD | Glykos Finland Oy (FI) | 2016-03-09 | — | — | EP | claimed |
| WO-2014177771-A1 | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD | GLYKOS FINLAND OY (FI) | 2014-11-06 | — | — | WO | claimed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-12553902-B2 | Methods, kits and compositions for diagnosing and treating renal disease | HILL'S PET NUTRITION, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| US-20260009800-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | UNIV ARIZONA (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| US-12491217-B2 | Compositions and methods for promoting healthy neural development in an unborn baby | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250164507-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CARDIOMYOPATHY IN A FELINE | Société des Produits Nestlé S.A. (CH) | 2025-05-22 | — | — | US | disclosed |
| EP-2053403-A2 | Affinity fishing for ligands and proteins receptors | Novo Nordisk A/S (DK) | 2009-04-29 | — | — | EP | disclosed |
| EP-1588173-B1 | AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS | NOVO NORDISK AS (DK) | 2008-11-26 | — | — | EP | disclosed |
| US-20060257875-A1 | Affinity screening using \"one-bead-one-compound\" libraries | CARLSBERG A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| US-20040142379-A1 | Affinity fishing for ligands and proteins receptors | CARLSBERG RESEARCH LABORATORY (DK) | 2004-07-22 | — | — | US | disclosed |
| WO-1998052129-A1 | CONSTITUTIONAL ANALYSIS OF PROTEIN DOMAINS | MACQUARIE RESEARCH LTD. (AU) | 1998-11-19 | — | — | WO | disclosed |
| EP-0425019-B1 | Methods and compositions employing certain lysozymes and endoglycosidases | PROCTER & GAMBLE (US) | 1995-01-11 | — | — | EP | disclosed |
| US-5041236-A | Antimicrobial methods and compositions employing certain lysozymes and endoglycosidases | THE PROCTER & GAMBLE COMPANY (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0425019-A1 | Methods and compositions employing certain lysozymes and endoglycosidases | THE PROCTER & GAMBLE COMPANY (US) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | CA1 2438/4885CA2 1492/4885CA9 1211/4885 |
| US-20260009800-A1 | METHODS OF DIAGNOSIS AND GUIDING TREATMENT OF VULVOVAGINAL SYMPTOMS AND FEMALE SEXUAL DYSFUNCTION | SHBG, GNRHR, STIM2 | CA1 1855/4885CA2 1683/4885CA9 782/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | CA1 2403/4885CA2 2828/4885CA9 2293/4885 |
| US-12553902-B2 | Methods, kits and compositions for diagnosing and treating renal disease | GLS, KYNU, AADAT | CA1 491/4885CA2 381/4885CA9 301/4885 |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | CA1 4348/4885CA2 4025/4885CA9 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.